BJUI compass最新文献

{"title":"Exploring patient and clinician opinions, perspectives and acceptance of the use of artificial intelligence in the histological diagnosis of prostate cancer","authors":"Lisa Browning,&nbsp;Abhisek Ghosh,&nbsp;Monica Dolton,&nbsp;Kate Hutton,&nbsp;Jacqueline Birks,&nbsp;Richard Scheffer,&nbsp;Ewart Stanislaus,&nbsp;James Crofts,&nbsp;Richard Colling,&nbsp;Richard Bryant,&nbsp;Clare Verrill","doi":"10.1002/bco2.70108","DOIUrl":"10.1002/bco2.70108","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to explore the opinions and attitudes of patients and clinicians regarding the use of artificial intelligence (AI) in the diagnosis of prostate biopsies, with a focus on acceptance and trust in the use of AI, and factors that may impact this.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Subjects and methods</h3>\u0000 \u0000 <p>Surveys were sent to patient members of UK-based prostate cancer support groups and to a group of clinicians managing patients with prostate cancer (or suspected prostate cancer).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 130 patient respondents, 94% expressed acceptance of AI assistance in the diagnosis of prostate biopsies when a pathologist retains responsibility for the final diagnosis, but regard it as the responsibility of the pathologist to decide whether AI is used in this setting. Similar responses were noted among the nine clinician respondents. Regarding factors with potential impact on acceptance of AI, an understanding of how the AI was tested and its performance in comparison with a pathologist was considered to be more important than how the technology was developed, and half (51%) of patients suggested that access to additional information might impact their acceptance of AI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Understanding the perspectives of stakeholders is key to the successful clinical implementation of AI in the histological diagnosis of prostate biopsies. Our study shows a high level of acceptance of AI for the diagnosis of prostate biopsies among patients if a pathologist retains oversight of the diagnosis and the decision as to when AI is used. Furthermore, it suggests similar levels of acceptance among clinicians. Our study provides insight into areas for educational focus to enhance understanding of AI in this setting.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12598096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145497606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary assessment of diagnostic performance and histologic concordance of renal mass biopsy with surgical pathology","authors":"Mitchell M. Huang,&nbsp;Cristina B. Arruza-Frau,&nbsp;Austin P. Drysch,&nbsp;Nicole Handa,&nbsp;Ridwan Alam,&nbsp;Behtash G. Nezami,&nbsp;Ashley E. Ross,&nbsp;Niraj K. Shenoy,&nbsp;Kent T. Perry,&nbsp;Hiten D. Patel","doi":"10.1002/bco2.70104","DOIUrl":"https://doi.org/10.1002/bco2.70104","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Improvements in imaging and technique have led to a greater role for renal mass biopsy (RMB) to risk-stratify localized renal masses. We sought to assess the contemporary diagnostic accuracy of RMB for identifying renal cell carcinoma (RCC) based on concordance with final surgical pathology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Consecutive patients undergoing RMB between 2013 and 2023 across an 11-hospital health system were identified. Concordance between RMB and final pathology for patients receiving partial or radical nephrectomy was compared. We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of RMB for identifying RCC among patients who underwent surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 733 patients underwent RMB with an overall non-diagnostic rate of 11% and most biopsies (67%) identified RCC. A total of 243 patients with surgical pathology were analysed, and 229 (94%) had RCC on surgical pathology. Excluding non-diagnostic cases, RMB had a 98% concordance with surgical pathology for RCC; RMB had 94% sensitivity, 71% specificity, 98% PPV and 42% NPV for identifying RCC with non-diagnostic cases considered as benign biopsies. For the nine RMB oncocytic cases receiving surgery, six (66%) were RCC and only two (22%) were confirmed oncocytomas. For patients with biopsy grade reported, 100% of high-grade RCC were confirmed while 26% of low-grade RCC were upgraded at nephrectomy (overall 80% concordance).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In a large, contemporary cohort of patients, RMB had high PPV and sensitivity for identifying RCC and high concordance for specific histology at nephrectomy. However, upgrading was common, and oncocytic lesions selected for surgery due to clinical suspicion often harboured RCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145469857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer","authors":"Austin Drysch,&nbsp;Kathryn E. Fink,&nbsp;Nicole Handa,&nbsp;Mitchell M. Huang,&nbsp;Sai Kumar,&nbsp;Yutai Li,&nbsp;Ridwan Alam,&nbsp;Amy E. Krambeck,&nbsp;Hiten D. Patel,&nbsp;Ashley E. Ross","doi":"10.1002/bco2.70105","DOIUrl":"10.1002/bco2.70105","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study is to evaluate whether prior Holmium laser enucleation of the prostate (HoLEP) affects the diagnostic accuracy of multiparametric prostate MRI (mpMRI) with PI-RADS scoring for detecting clinically significant prostate cancer (csPCa) on biopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>We queried the Northwestern Electronic Data Warehouse for all patients who underwent mpMRI followed by prostate biopsy. Demographic information, mpMRI data including PI-RADS score and biopsy data including Gleason grade (GG) were collected. Patients were stratified based on prior HoLEP and highest PI-RADS score of index lesion on MRI. The outcome of interest was detection of csPCa (GG ≥ 2) on biopsy. Logistic regression was performed to assess the impact of prior HoLEP on the detection of csPCa at time of biopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 8937 patients met inclusion criteria, of which 97 patients (1.1%) had prior HoLEP. HoLEP specimen revealed benign pathology in 38 patients (39.2%), GG1 in 32 patients (33.0%), GG2 in 25 patients (25.8%) and GG3 in 2 patients (2.1%). Average time from HoLEP to mpMRI was 11.5 months. The post-HoLEP group had lower prostate volumes (median 25.0 vs. 47.0 cc; <i>p</i> &lt; 0.001) and PSA density (median 0.06 vs. 0.12 ng/ml²; <i>p</i> &lt; 0.001). Rates of csPCa detection based on highest PI-RADS score were comparable between control and HoLEP groups. Prior HoLEP did not significantly affect the detection of csPCa on multivariable analysis adjusting for age, race, PI-RADS, family history of PCa, and PSA density (OR = 0.97; 95% CI: 0.60–1.57).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>PI-RADS remains a reliable predictor of csPCa after HoLEP despite anatomic alterations. mpMRI should continue to guide biopsy and risk stratification in this population, though larger validation is warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12586339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-modality imaging problem-solving for pelvic splenosis on PSMA PET in a patient with recurrent prostate cancer","authors":"James Morgan,&nbsp;Anurag Anugu,&nbsp;Jorge D. Oldan,&nbsp;Michael C. Repka,&nbsp;Steven P. Rowe","doi":"10.1002/bco2.70090","DOIUrl":"10.1002/bco2.70090","url":null,"abstract":"&lt;p&gt;We present the case of a 73-year-old man with a history of remote splenectomy after trauma, Gleason 3 + 4 prostate adenocarcinoma treated with external beam radiation and 6 months of androgen deprivation therapy 11 years prior to presentation, and T3N0M0 colonic adenocarcinoma treated with hemicolectomy 5 years prior to presentation. He was found to have an increasing PSA on multiple surveillance labs up to 0.94 ng/mL prior to presentation. &lt;sup&gt;18&lt;/sup&gt;F-DCFPyL prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) was performed to evaluate for recurrent disease or sites of metastasis. That scan showed mild uptake in the peripheral zone of the prostate as well as a 2.3 cm focus of moderate uptake in the sigmoid colon that was considered concerning for a malignant implant (Figure 1A). However, as splenic tissue is also known to normally express PSMA, splenosis was also included on the differential.&lt;span&gt;&lt;sup&gt;1-4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;MRI was performed with a nondiagnostic evaluation of the prostate and further characterization of the colonic lesion, which appeared to arise from the distal sigmoid colon (Figure 1B). Comparison to prior imaging showed stable size over multiple prior scans, raising the possibility of a small gastrointestinal stromal tumour (GIST), an entity that is also known to express PSMA.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Particularly considering the history of colon cancer, a 2-deoxy-2-[&lt;sup&gt;18&lt;/sup&gt;F]-fluoro-D-glucose (FDG) PET was performed, showing a grossly stable lesion of the sigmoid colon with similar uptake to the surrounding bowel (Figure 1C). A surveillance colonoscopy was not able to identify the lesion of interest and also did not show any other evidence of colon cancer recurrence.&lt;/p&gt;&lt;p&gt;After discussion at the tumour board, the decision was made to perform &lt;sup&gt;99m&lt;/sup&gt;Tc-sulphur colloid liver-spleen scan with single-photon emission computed tomography (SPECT)/CT to rule out splenosis prior to attempting tissue sampling. Although there have been cases that have indicated that heat-damaged tagged red blood cells can have improved sensitivity for splenic tissue,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; that agent is not readily available at our institution, whereas &lt;sup&gt;99m&lt;/sup&gt;Tc-sulphur colloid can be conveniently obtained. Ultimately, the &lt;sup&gt;99m&lt;/sup&gt;Tc-sulphur colloid liver-spleen scan showed increased uptake within the lesion, consistent with implanted splenic tissue (Figure 1D).&lt;/p&gt;&lt;p&gt;With widespread usage of PSMA-targeted radiotracers, it is important to remain cognizant of the potential pitfalls that can be encountered. Similarly, a thorough review of the patient history, prior images and utilization of other imaging modalities are frequently essential to effectively troubleshoot abnormal presentations of disease and arrive at the correct diagnosis without subjecting the patient to unnecessary invasive procedures. In this case, splenosis and colonic malignancy were included on the initial differenti","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12582902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary meetings for lower urinary tract symptoms and benign prostate hyperplasia","authors":"Emilien Seizilles de Mazancourt,&nbsp;Nadia Abid,&nbsp;Gaele Pagnoux,&nbsp;Olivier Rouvière,&nbsp;Ricardo Codas Duarte,&nbsp;Alain Ruffion,&nbsp;Hakim Fassi Fehri","doi":"10.1002/bco2.70089","DOIUrl":"10.1002/bco2.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To describe a single academic centre experience in the establishment of Multidisciplinary Meetings (MDM) for the management of male non-neurogenic Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Hyperplasia (BPH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>Retrospective analysis of all the cases discussed in MDM for LUTS/BPH in our academic centre over a year, and analysis of the implementation rates, reasons for failure of implementation and discrepancies between the proposal and the final decision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over one year, 108 cases were discussed. The implementation rate of the recommendation was 71% (77/108). The reasons for the failure of implementation of the recommendation were patient preference in 6 (5%), lost to follow-up in 13 (12%), consultant decision in 4 (4%), patient deterioration or new comorbidities in 2 (2%), improvement of LUTS symptoms in 4 (4%) and the suggested technique was not available for technical reasons in 1 (1%). The consultant's proposal was validated in 98 cases (90.7%) and a different decision was made in 9 cases (8.3%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The establishment of a MDM for male LUTS/BPH is feasible and could contribute to the improvement of the management of patients. Further studies are needed to evaluate all its aspects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12582637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nephrolithiasis risk factors for obese patients on 24-hour urine collection metabolic evaluation","authors":"Mark I. Sultan,&nbsp;Satoshi Yamazaki,&nbsp;Shady A. Ibrahim,&nbsp;Hadeel Haddad,&nbsp;Antoinette Abdelmalek,&nbsp;Sohrab N. Ali,&nbsp;Mac Kinnly T. Knoerzer,&nbsp;Muhammed A. M. Hammad,&nbsp;Ramy F. Youssef","doi":"10.1002/bco2.70103","DOIUrl":"https://doi.org/10.1002/bco2.70103","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Twenty-four-hour urine collections are obtained as part of the metabolic workup for nephrolithiasis to identify modifiable abnormalities for stone prevention. We sought to discern trends in the prevalence of abnormalities based on body mass index (BMI) (kg/m²).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>All unique Litholink™ 24-Hour Urine outcomes for nephrolithiasis prior to medical or dietary therapy obtained at our institution between 2004 and 2020 were retrospectively reviewed. Patients with anthropometric data were classified according to body mass index (BMI) as underweight (&lt;18.5), normal (18.5–25), overweight^25-30 and obese (&gt;30). Litholink™ 24-Hour Urine gender specific reference ranges were used to define abnormalities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1372 patients were included. The mean age was 56 <span></span><math>\u0000 <semantics>\u0000 <mrow>\u0000 <mo>±</mo>\u0000 </mrow>\u0000 <annotation>$$ pm $$</annotation>\u0000 </semantics></math> 15.3 (53.5% male, 46.5% female). Cumulatively, 30.7% (421/1372) were obese, 32.9% (452/1372) overweight, 33.4% (458/1372) normal and 3.0% (41/1372) underweight. Overall, elevated urine sodium was the most common metabolic abnormality (52.8%). In obese stone formers, hypercalciuria (p = 0.027), hyperoxaluria (p &lt; 0.001), elevated urine sodium (p &lt; 0.001), hyperuricosuria (p &lt; 0.001) low urine pH (p &lt; 0.001) and high uric acid supersaturation (p &lt; 0.001) were more likely compared to normal BMI stone formers. Underweight patients demonstrated greater likelihood of oliguria (p = 0.001), without adjustment for weight, and hypocitraturia (p = 0.001) compared to normal BMI stone formers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Body weight differences are associated with different risk profiles on 24-hour urine collection. Obese, and to a letter degree, underweight patients are more likely to harbour metabolic derangements on a 24-hour urine analysis compared to patients with normal BMI, thus underscoring the importance of directed medical therapy for stone formers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer","authors":"Esther H. J. Hamoen,&nbsp;Bas Israël,&nbsp;Marloes van der Leest,&nbsp;Erik B. Cornel,&nbsp;O. Sjoerd Klaver,&nbsp;Rianne J. Hendriks,&nbsp;Jeroen Veltman,&nbsp;Inge M. van Oort,&nbsp;Gerjon Hannink,&nbsp;J. Alfred Witjes,&nbsp;Jelle O. Barentsz,&nbsp;Maroeska M. Rovers","doi":"10.1002/bco2.70087","DOIUrl":"https://doi.org/10.1002/bco2.70087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To study the impact of the new MRI pathway and conventional transrectal ultrasound-guided systematic biopsies (TRUSGB) on anxiety and HRQoL in men with suspected PCa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>A secondary analysis was performed of a randomized clinical trial including 626 biopsy-naïve patients. All patients underwent mpMRI and TRUSGB. Men with suspicious lesions on mpMRI underwent MRGB prior to TRUSGB. Anxiety was measured by State–Trait Anxiety Inventory-Trait Scale (STAI-6), completed at baseline, directly after mpMRI, MRGB, TRUSGB, after two/three weeks, and six months. HRQoL was measured by EuroQol (EQ-5D-5L), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and Prostate Cancer Module (QLQ-PR25). Outcomes were compared between patients that underwent mpMRI and TRUSGB and patients that underwent mpMRI, MRGB and TRUSGB. Differences were considered relevant if the 95% confidence interval exceeded the minimal important clinical difference.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No relevant differences were seen in anxiety scores and generic HRQoL at different time points in patients that underwent mpMRI, TRUSGB and MRGB compared to patients that underwent mpMRI and TRUSGB. Patients that underwent mpMRI, MRGB and TRUSGB reported lower incontinence aid and hormonal treatment-related symptom scores after 6 months compared to patients that underwent mpMRI and TRUSGB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In men suspected of PCa, no differences were observed in anxiety levels or generic HRQoL scores across different diagnostic pathways. However, lower PCa-specific HRQoL subscores were noted in patients who underwent mpMRI, MRGB and TRUSGB.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, treatment patterns and healthcare resource use of Finnish men with prostate cancer","authors":"Ruotsalainen Jarno,&nbsp;Kallio Alvar,&nbsp;Korolainen Minna A,&nbsp;Raittinen Paavo,&nbsp;Nevalaita Liina,&nbsp;Korhonen Maarit Jaana,&nbsp;Matikainen Mika Petri","doi":"10.1002/bco2.70098","DOIUrl":"https://doi.org/10.1002/bco2.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterize patients diagnosed with prostate cancer (PC) in Finland in 2015–2019 and to follow-up the treatment patterns and healthcare resource use for patients with nonmetastatic PC (nmPC) and metastatic PC (mPC) until the end of 2020.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>PC cases were identified from the Finnish Cancer Registry and the Care Register for Health Care. Data on inpatient and outpatient diagnoses, outpatient medicine use and sociodemographics were sourced from nationwide registers. Data on Gleason scores and in-hospital medication were available for a subset of the patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 25 045 men were diagnosed with PC in 2015–2019. The median age was 71 years, and 28% of these cases were considered as de novo mPC or progressed to mPC within one year from diagnosis. Of the whole cohort with PC, 1368 (5.5%) died within one year (2.3% from PC). Altogether, 70% received active treatment within one year from diagnosis (nmPC cohort: 59%; mPC cohort: 97%). In the nmPC cohort, the most common treatments within the first year were radiotherapy (31%), androgen deprivation therapy (ADT) (25%) and radical prostatectomy (25%). In the mPC cohort, ADT (92%), radiotherapy (38%) and first-generation antiandrogens bicalutamide or flutamide (22%) were the most common first-year treatments. The use of first-generation antiandrogens declined, and the use of second-generation antiandrogens increased towards the end of the study period. The total number of all-cause healthcare contacts per patient year was higher for mPC than for nmPC (61 vs. 29 contacts).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This large nationwide cohort study suggests that, in Finland, PC is generally diagnosed in the localized phase. As expected, the disease burden seems to be higher among men with metastatic disease. The estimated high proportion of patients with mPC at or soon after diagnosis should be interpreted with caution.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Penile cancer in French Guiana: Epidemiology, histopathology and clinical aspects","authors":"Khalil Chalhoub,&nbsp;Bawa Nonoa,&nbsp;Vincent Molinier,&nbsp;Vincent Ravery","doi":"10.1002/bco2.70096","DOIUrl":"10.1002/bco2.70096","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To study the characteristics of penile cancer in French Guiana (FG)— a French overseas department in South America. Indeed, penile cancer is a rare malignancy with significant geographic and socioeconomic disparities. While its epidemiology is well-documented in mainland France, data from FG remain limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>We conducted a retrospective analysis of 22 cases of primary penile cancer diagnosed between 2004 and 2024 at the Centre Hospitalier de Kourou. Demographic, clinical, histopathological, and risk factor data were collected and reviewed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The average incidence was 1.07 cases per year, with a mean age at diagnosis of 54.9 years. Notably, 19% of patients were under 40 years. The Bushinengue population (descendants of escaped African slaves) accounted for 54.5% of cases. The most common risk factor was lack of circumcision (100%), followed by HPV-16 infection (40.9%). Most tumours were exophytic (68.2%), distal (72.7%), with a median size of 3.5 cm. Squamous cell carcinoma was the predominant histological type (90.9%), with 56.3% being well differentiated. Lymph node involvement was present in 68.2% of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The incidence of penile cancer in FG appears higher than in neighbouring regions, potentially due to regional underreporting and cross-border healthcare access. The disproportionate impact on the Bushinengue population, younger age at diagnosis and advanced disease at presentation likely reflect cultural practices, low circumcision rates and barriers to early care. This first study on penile cancer in FG highlights the role of non-circumcision and HPV-16 infection as major risk factors. Public health efforts should prioritize HPV vaccination and early diagnostic access in vulnerable populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12521786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145309999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gross haematuria in the era of anticoagulant therapy – Implications on treatment and diagnostic approaches in a large emergency department patient population","authors":"Yushan Yang,&nbsp;Johanna Seidl,&nbsp;Simon Udo Engelmann,&nbsp;Maximilian Haas,&nbsp;Roman Mayr,&nbsp;Maximilian Burger,&nbsp;Johannes Breyer,&nbsp;Markus Resch","doi":"10.1002/bco2.70099","DOIUrl":"10.1002/bco2.70099","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Treatment with anticoagulants or antiplatelet drugs can provoke gross haematuria. In some cases, this may demask urologic malignancies. The goal of this study was to determine the influence of anticoagulants and antiplatelet drugs on the diagnosis and therapy of patients with gross haematuria who presented in the emergency department.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study analysed patients presenting with gross haematuria between January 1st, 2021 and December 31st, 2021 in a single centre university hospital. Information on pre-existing conditions, anticoagulant and antiplatelet medication, and the further diagnostic and treatment course was gathered with a follow-up time until December 31st, 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nearly half of the 541 patients (49.5%) presenting with gross haematuria were taking anticoagulant or antiplatelet medication. Patients receiving these medications were more likely to need bladder irrigation (p &lt; 0.001). They were also more likely to be hospitalized (p &lt; 0.001) and receive operative intervention (p = 0.011). The most common cause for haematuria was malignant tumours. A malignant urologic disease was diagnosed in 27% of the patients. Among those who were diagnosed with a malignant disease, the number of patients taking anticoagulant medication was higher (p = 0.005). In a follow-up of 3 months, no thromboembolic events were observed after stopping or pausing anticoagulation or antiplatelet treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Clinically significant gross haematuria is often associated with the intake of anticoagulant or antiplatelet medication and can unmask underlying malignant diseases. The intake of anticoagulation or antiplatelet therapy should not be a reason to postpone diagnostic and therapeutic measures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12504806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}